{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:20:54Z","timestamp":1772490054394,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Hepatitis B surface antigen (HBsAg) and viral load are important clinical indicators for antiviral therapy. Few studies have evaluated viral sequence biomarkers predicting the risk of hepatocellular carcinoma (HCC) in the stage, which show a low serological response (HBsAg &amp;lt; 100 IU\/ml) and high viral levels (HBV DNA &amp;gt; 2,000 IU\/ml). This study aims to determine the trend of the biological prevalence within the pre-S\/S regions of special model of inactive CHB infection.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We used Sanger sequencing, quantitative HBV serology (HBeAg and HBsAg), and liver function index to identify whether HBV genome sequences are associated with long-term risk of further HCC progression in special inactive CHB infection.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> HBV sequencing analysis of 28 CHB patients with special infectious pattern showed higher genetic diversity among four opening reading frames (ORFs) (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). However, dN\/dS ratios of HBsAg and pre-C\/C regions in the experimental group showed no significantly different from those in the HCC group (<jats:italic>p<\/jats:italic> = 0.06), while significantly lower in polymerase and HBxAg regions of the experimental group (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). In addition, seven positively selected sites were identified in pre-S1, five in pre-S2, and four in S, in which five sites (128H\/135Q\/135R\/139L\/141P) were among \u201c\u03b1\u201d determinant.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> These mutations in the pre-S\/S region might be associated with the HCC phenotype of low HBsAg expression, with the P region possibly impacting high viral loads. Increased viral diversity across the HBV genome is also associated with low levels of HBsAg. The cumulative evolutionary changes in the HBV pre-S\/S regions shows that facilitate immune evasion should be monitored individually. Due to the similarity of evolutionary characteristics in HCC, low serological responses and high viremia may be associated with the risk of further disease progression.<\/jats:p>","DOI":"10.3389\/fpubh.2021.633792","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T05:22:23Z","timestamp":1619414543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Evolutionary Analysis of Pre-S\/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg &lt; 100 IU\/ml"],"prefix":"10.3389","volume":"9","author":[{"given":"Yingping","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0140-6736(10)60274-7","article-title":"Acute liver failure","volume":"376","author":"Bernal","year":"2020","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos (t) ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jmv.24601","article-title":"Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B","volume":"89","author":"Chuaypen","year":"2017","journal-title":"J Med Virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/liv.12735","article-title":"HBsAg quantifcation to optimize treatment monitoring in chronic hepatitis B patients","volume":"35","author":"Martinot-Peignoux","year":"2015","journal-title":"Liver Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest."},{"key":"B6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu Rev Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00535-012-0668-y","article-title":"Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog","volume":"48","author":"Tseng","year":"2013","journal-title":"J Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jcv.2013.08.010","article-title":"Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J Clin Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1136\/gutjnl-2015-309300","article-title":"Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B","volume":"66","author":"Bayliss","year":"2017","journal-title":"Gut."},{"key":"B10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol Biol Evol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nmeth.4285","article-title":"ModelFinder: fast model selection for accurate phylogenetic estimates","volume":"14","author":"Kalyaanamoorthy","year":"2017","journal-title":"Nat Methods."},{"key":"B12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/sysbio\/sys029","article-title":"MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space","volume":"61","author":"Ronquist","year":"2012","journal-title":"Syst Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e47046","DOI":"10.1371\/journal.pone.0047046","article-title":"Read length versus depth of coverage for viral quasispecies reconstruction","volume":"7","author":"Zagordi","year":"2012","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: molecular evolutionary genetics analysis version 6.0","volume":"30","author":"Tamura","year":"2013","journal-title":"Mol Biol Evol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1101\/gr.092759.109","article-title":"Circos: an information aesthetic for comparative genomics","volume":"19","author":"Krzywinski","year":"2009","journal-title":"Genome Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/molbev\/msm088","article-title":"PAML 4: phylogenetic analysis by maximum likelihood","volume":"24","author":"Yang","year":"2007","journal-title":"Mol Biol Evol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/molbev\/msi097","article-title":"Bayes empirical bayes inference of amino acid sites under positive selection","volume":"22","author":"Yang","year":"2005","journal-title":"Mol Biol Evol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41598-017-02010-w","article-title":"Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg \u2264 200 IU\/ml","volume":"7","author":"Yao","year":"2017","journal-title":"Sci Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jvh.12736","article-title":"Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: a community-based real world study","volume":"24","author":"Wong","year":"2017","journal-title":"J Viral Hepat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/jgh.14032","article-title":"Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk","volume":"33","author":"Yang","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"B21","first-page":"105","article-title":"The role of HBsAg levels in the current management of chronic HBV infection","volume":"27","author":"Honer Zu Siederdissen","year":"2014","journal-title":"Ann Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/ajg.2016.109","article-title":"Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg","volume":"111","author":"Wang","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/hep.29235","article-title":"Low-level viremia in hepatitis B patients on antiviral treatment: can we ignore it?","volume":"66","author":"Min","year":"2017","journal-title":"Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.28640","article-title":"Hepatitis B surface antigen loss: not all that we hoped it would be","volume":"64","author":"Nathanson","year":"2016","journal-title":"Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.25592","article-title":"Impact of hepatitis B virus (HBV) preS\/S genomic variability on HBV surface antigen and HBV DNA serum levels","volume":"56","author":"Pollicino","year":"2012","journal-title":"Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","article-title":"Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up","volume":"14","author":"Brouwer","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jvh.12498","article-title":"Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleo(t)ide analogue therapy","volume":"23","author":"Velay","year":"2016","journal-title":"J Viral Hepat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/j.1349-7006.2009.01309.x","article-title":"Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcino genesis in Asian children","volume":"100","author":"Abe","year":"2009","journal-title":"Cancer Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/jnci\/djp180","article-title":"Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis","volume":"101","author":"Liu","year":"2009","journal-title":"J Natl Cancer Inst."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/j.1572-0241.2008.01974.x","article-title":"HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study","volume":"103","author":"Fang","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2013.06.018","article-title":"Hepatitis B virus splicing is enhanced prior to development of hepatocellular carcinoma","volume":"59","author":"Bayliss","year":"2013","journal-title":"J Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/jvh.12212","article-title":"Short duration of lamivudine for prevention of HBV transmission in pregnancy: lack of potency and selection of resistance mutations","volume":"21","author":"Ayres","year":"2014","journal-title":"J Viral Hepat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jcv.2012.01.003","article-title":"Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples","volume":"53","author":"Servant-Delmas","year":"2012","journal-title":"J Clin Virol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.633792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T05:22:27Z","timestamp":1619414547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.633792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2021.633792"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.633792","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"article-number":"633792"}}